Soligenix Inc. (NASDAQ: SNGX) is advancing a novel therapeutic approach for cutaneous T-cell lymphoma through its development of HyBryte™, also known as synthetic hypericin. CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages, creating a challenging diagnostic and treatment landscape that Soligenix aims to address.
HyBryte is a visible light-activated photodynamic therapy designed specifically for the treatment of early-stage CTCL. Unlike traditional ultraviolet-based phototherapies, which can carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum. This mechanism allows for targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue, potentially offering a safer therapeutic option for patients.
Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, with regulatory approvals being sought worldwide following successful completion of the second Phase 3 study. For further information about the company's development programs, visit https://www.Soligenix.com.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Beyond HyBryte, the company's development programs in this business segment include expansion of synthetic hypericin into psoriasis, its first-in-class innate defense regulator technology dusquetide for the treatment of inflammatory diseases including oral mucositis in head and neck cancer, and development for Behçet's disease.
The company's Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax™, the company's vaccine candidate for the prevention of COVID-19. These programs incorporate Soligenix's proprietary heat stabilization platform technology known as ThermoVax® and have been supported with government grants and contract funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The advancement of HyBryte represents a significant development in the treatment landscape for CTCL, a rare cancer that has historically presented diagnostic and therapeutic challenges. By targeting malignant cells with greater specificity and potentially reducing long-term safety concerns associated with traditional phototherapies, this approach could improve patient outcomes while addressing critical gaps in rare disease treatment. The latest news and updates relating to Soligenix are available at https://ibn.fm/SNGX.
